Related Experiment Video
Updated: Jan 4, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a
Michele Marchioni1,2,3,4, Marta Di Nicola1,2, Giulia Primiceri1,3,4
1Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio University of Chieti, Chieti, Italy.
Purpose:
Docetaxel represent the standard of care in patients with metastatic, hormone sensitive prostate cancer. However, androgen receptor axis targeted therapies have also been shown to be effective. We aimed to analyze findings in randomized controlled trials investigating first-line treatment for hormone sensitive prostate cancer.
Materials And Methods:
We systematically reviewed the literature according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) criteria and the PICO (Population, Intervention, Comparator, Outcomes) methodology. Outcomes of interest were overall and progression-free survival, and the rate of high grade adverse events.
Results:
No treatment was superior to docetaxel in terms of overall survival. However, abiraterone (HR 0.89, 95% CI 0.76-1.05), enzalutamide (HR 0.90, 95% CI 0.69-1.19) and apalutamide (HR 0.90, 95% CI 0.67-1.22) showed nonstatistically significant lower overall mortality rates than docetaxel. Abiraterone (HR 0.71, 95% CI 0.59-0.86), enzalutamide (HR 0.61, 95% CI 0.49-0.75) and apalutamide (HR 0.74, 95% CI 0.57-0.95) also showed statistically significant lower disease progression rates than docetaxel. Furthermore, abiraterone (OR 0.83, 95% CI 0.56-1.21) showed no statistically significant lower rate of high grade adverse events compared to docetaxel. Finally, enzalutamide (OR 0.56, 95% CI 0.35-0.92) and apalutamide (OR 0.44, 95% CI 0.24-0.79) showed statistically significant lower rates of high grade adverse events compared to docetaxel.
Conclusions:
Treatment with androgen receptor axis targeted therapies combined with androgen deprivation therapy in patients with hormone sensitive prostate cancer did not offer a statistically significant advantage in overall survival compared to the standard, docetaxel. However, it was associated with a lower disease progression rate. Moreover, apalutamide and enzalutamide offer a better safety profile.
Insights
New androgen receptor axis targeted therapies show promise for metastatic hormone-sensitive prostate cancer, reducing disease progression and improving safety compared to docetaxel, though overall survival benefits are not yet statistically significant.
Area of Science:
- Oncology
- Urology
- Clinical Trials
Background:
- Docetaxel is the current standard of care for metastatic hormone-sensitive prostate cancer.
- Androgen receptor axis targeted therapies have emerged as effective treatment options.
Purpose of the Study:
- To systematically review randomized controlled trials comparing first-line treatments for hormone-sensitive prostate cancer.
- To analyze overall survival, progression-free survival, and high-grade adverse events.
Main Methods:
- Systematic literature review adhering to PRISMA criteria.
- PICO methodology used for outcome assessment (Population, Intervention, Comparator, Outcomes).
- Key outcomes: overall survival, progression-free survival, and high-grade adverse events.
Main Results:
- No treatment demonstrated statistically significant superiority over docetaxel in overall survival.
- Abiraterone, enzalutamide, and apalutamide showed statistically significant lower disease progression rates compared to docetaxel.
- Enzalutamide and apalutamide exhibited significantly lower rates of high-grade adverse events than docetaxel.
Conclusions:
- Androgen receptor axis targeted therapies combined with androgen deprivation therapy do not offer a statistically significant overall survival advantage over docetaxel.
- These novel therapies are associated with reduced disease progression.
- Apalutamide and enzalutamide present a more favorable safety profile.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:15Drugs that Stabilize Microtubules